Compugen Ltd. (NASDAQ: CGEN) today announced that its President and Chief Executive Officer, Dr. Anat Cohen-Dayag, will be presenting at the Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15. The title of her presentation is "Predictive Discovery of Novel, Targeted Medicines."
The presentation will be available after the conference on Compugen's website, at http://www.cgen.com
About Compugen
Compugen is a leading therapeutic product
discovery company focused on therapeutic proteins and monoclonal
antibodies to address important unmet needs in the fields of immunology
and oncology. Unlike traditional high throughput trial and error
experimental based discovery, Compugen utilizes a broad and continuously
growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in silico
(by computer) prediction and selection of product candidates, which are
then advanced in its Pipeline Program to the pre-IND stage. The
Company's business model primarily involves collaborations covering the
further development and commercialization of product candidates from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. In 2012,
Compugen established operations in California for the development of
oncology and immunology monoclonal antibody therapeutic candidates
against Compugen-discovered drug targets. In 2002, Compugen established
an affiliate, Evogene Ltd., (www.evogene.com)
(TASE:
EVGN.TA), to utilize certain of the Company's in silico
predictive discovery capabilities in agricultural biotechnology. For
additional information, please visit Compugen's corporate website at www.cgen.com.
Contacts:
Compugen Ltd.
Tsipi Haitovsky, Global Media Liaison
+972-52-598-9892
tsipih@netvision.net.il
